ArticleJournal of neuroendovascular therapy2025
Submucosal Esophageal Hematoma: A Rare Hemorrhagic Complication Following Neuroendovascular Therapy.
Article in Journal of neuroendovascular therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- "Spontaneous Intramural Esophageal Hematoma Associated with Uncontrolled Hypertension: Case Report and Review".International medical case reports journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Submucosal esophageal hematoma (SEH) is a rare complication of neuroendovascular therapy, and there are insufficient data on the management of antithrombotic therapy in cases of SEH. We report a case of SEH following flow diverter stenting for an unruptured cerebral aneurysm, successfully managed with conservative treatment, including short-term interruption of antiplatelet therapy. Case Presentation: An 80-year-old woman on clopidogrel and aspirin underwent Pipeline flow diversion with adjunctive coil embolization for an unruptured right internal carotid-posterior communicating artery aneurysm under general anesthesia without complications. Postoperatively, the patient developed chest pain, and CT revealed wall thickening from the middle to lower esophagus, leading to a diagnosis of SEH. SEH in this case was likely caused by a combination of antiplatelet therapy, anticoagulants, nasogastric tube insertion, and mechanical stimulation from intubation and extubation during the operation. The patient was managed conservatively with fasting and discontinuation of antiplatelet therapy. After CT confirmed hemostasis, antiplatelet therapy was resumed with intravenous ozagrel sodium on postoperative day 3, switching to oral prasugrel on day 7. Upper gastrointestinal endoscopy (UGE) on day 8 showed the submucosal hematoma replaced by ulcers and fistula formation. UGE on day 15 showed improvement, and CT on day 23 confirmed hematoma resolution. The patient was discharged on day 24 without symptoms or complications. Conclusion: In addition to previously reported cases, the presented case suggests that conservative management with temporary antiplatelet interruption and early resumption after hemostasis can lead to favorable outcomes in SEH cases associated with neuroendovascular therapy requiring antiplatelet therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.